Vicore Pharma AB
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Vicore Pharma AB sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Vicore Pharma AB: 3 sponsored US clinical trials, 1 recruiting.
Vicore Pharma AB sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Idiopathic Pulmonary Fibrosis (IPF), with 1 trials.
Upper-quartile sponsor footprint
Vicore Pharma AB sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
NCT05330312
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
NCT04880642
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Vicore Pharma AB pipeline
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Idiopathic Pulmonary Fibrosis (IPF) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vicore Pharma AB: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Vicore Pharma AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Vicore Pharma AB page
3 registered trials is a research-attention snapshot, not an endorsement of Vicore Pharma AB or any single study.
- 1 of Vicore Pharma AB's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Idiopathic Pulmonary Fibrosis (IPF) is the condition Vicore Pharma AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Idiopathic Pulmonary Fibrosis (IPF) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vicore Pharma AB pipeline card: 3 registered trials from official public datasets.Report a data error.